Singapore, Feb. 3 -- Japan-based Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately JPY 1.39 billion ($8.8 million) in six R&D projects for the development of drugs, diagnostics and vaccines for malaria, tuberculosis (TB), and neglected tropical diseases (NTDs).

For malaria,the GHIT Fund is investing JPY 648 million ($4.1 million) in a global partnership aimed at developing an mRNA vaccine to reduce infection and transmission of vivax malaria. This project is being led by Mahidol University and Chulalongkorn University in Thailand, and Ehime University in Japan. The investment builds on a prior GHIT-supported projectthat received approximately JPY 70 million ($0.4 million) between 2023 and 2...